Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat
Dr. Reddy's (RDY) stock drops after missing Q1 FY27 earnings & revenue estimates. Semaglutide issues & Trump tariff plans weigh on shares.
Dr. Reddy's made less money than people expected last quarter, and they're having trouble with an important medicine called semaglutide. When a company misses its targets, it tells you to watch more carefully for whether things are getting better or staying hard.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.